NMRD - Nemaura Medical Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.0000
+0.0200 (+2.04%)
As of 11:03AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.9800
Open1.0000
Bid0.9575 x 1400
Ask1.0000 x 1000
Day's Range1.0000 - 1.0150
52 Week Range0.8000 - 3.9800
Volume30,700
Avg. Volume105,646
Market Cap207.656M
Beta (3Y Monthly)2.40
PE Ratio (TTM)N/A
EPS (TTM)-0.0230
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    Nemaura Announces Successful Completion of Summative Human Factors Usability Study for SugarBEAT®

    Nemaura Medical, Inc. (NMRD), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced that it has successfully completed two summative human factors usability studies for SugarBEAT®.  The usability studies were conducted according to the U.S. Food and Drug Administration (FDA) guidance on ‘Applying Human Factors and Engineering to Medical Devices,’ in preparation for submission of its medical device application to the FDA for SugarBEAT®.

  • GlobeNewswire10 days ago

    Nemaura Announces Addition of New Predictive Alert Functionality to SugarBEAT®

    Loughborough, England , April 16, 2019 -- April 16, 2019 – Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on the development of SugarBEAT® as.

  • GlobeNewswire29 days ago

    Nemaura CEO Provides Update to Shareholders

    Loughborough, England, March 28, 2019 -- Loughborough, England – March 28, 2019 – Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on the.

  • GlobeNewswirelast month

    Nemaura Medical Announces Exclusive License and Supply Agreement for SugarBEAT® in the GCC Region

    Loughborough, England – March 12, 2019 – Nemaura Medical, Inc. (NMRD), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced that it has signed an exclusive license and supply agreement for SugarBEAT® with TPMENA in the Gulf Cooperation Council (GCC) Region, which includes Bahrain, Kuwait, Saudi Arabia, Oman and United Arab Emirates. TPMENA is a distributor of medical devices in the GCC Region, backed by Cigalah group.

  • GlobeNewswire2 months ago

    Nemaura Reports Third Quarter 2018 Financial Results

    Loughborough, England – Nemaura Medical, Inc. (NASDAQ: NMRD) nemauramedical.com, a medical technology company focused on the development of SugarBEAT® as a non-invasive,.

  • GlobeNewswire2 months ago

    Nemaura Announces Dr. Fred Schaebsdau to Lead Strategy and Business Development

    February 11, 2019 – Nemaura Medical, Inc. (NMRD) nemauramedical.com, a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced that Dr. Fred Schaebsdau, MD, PhD, MBA has joined Nemaura to lead strategy and business development. Dr. Schaebsdau will advance Nemaura’s commercial strategy for its planned launch of SugarBEAT® in Europe, and advise regarding its upcoming 510(k) submission to the United States Food and Drug Administration.

  • GlobeNewswire3 months ago

    Nemaura Medical Announces Grant of U.S. Patent for SugarBEAT® Glucose Sensing Algorithm

    February 7, 2019 – Nemaura Medical Inc. (NMRD) nemauramedical.com, a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (“CGM”) for use by diabetics and pre-diabetics, today announced the grant of U.S. Patent 10,092,224, Cumulative Measurement of an Analyte. SugarBEAT® CGM utilizes a proprietary, daily disposable adhesive skin-patch system connected to a small form factor rechargeable transmitter, connected via Bluetooth to a specially designed mobile application, which displays glucose readings at five-minute intervals throughout the day.

  • GlobeNewswire3 months ago

    Nemaura Medical Announces Improvement to SugarBEAT® Continuous Glucose Monitor

    Loughborough, England –Nemaura Medical, Inc. (NMRD) nemauramedical.com a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced that it has substantially advanced the use-case for SugarBEAT® to improve management of glucose levels by spending more time in range. SugarBEAT® CGM utilizes a proprietary daily disposable adhesive skin-patch system connected to a small form factor rechargeable transmitter, connected via Bluetooth to a specially designed mobile application, which displays glucose readings at five-minute intervals throughout the day. Nemaura has previously achieved industry-leading, skin-patch warm-up periods of less than one hour meaning that reliable glucose readings can be expected one hour after application of the skin-patch.

  • GlobeNewswire4 months ago

    Nemaura Announces Completion of Key Stages of Technical File Review for SugarBEAT® CE Mark Approval

    Nemaura Medical Inc. (NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by people with diabetes and pre-diabetics, today announced that two of the three key stages for the CE Mark approval of sugarBEAT® have been completed. Dr. Faz Chowdhury, CEO of Nemaura, will host an investor webinar and live Q&A at 10am ET today.

  • GlobeNewswire4 months ago

    Dawson James Securities Announces Closing of $2.0 Million Offering for Nemaura Medical, Inc.

    BOCA RATON, Fla., Dec. 20, 2018 -- Dawson James Securities, Inc. in conjunction with Nemaura Medical (Nasdaq: NMRD) announced today the closing of a public offering of.

  • GlobeNewswire4 months ago

    Nemaura to Host Investor Webinar on December 21 to Provide Update on Recent Developments

    LOUGHBOROUGH, England - Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose.

  • Why Micro Cap Nemaura Medical Crashed 39.5% Today
    Motley Fool4 months ago

    Why Micro Cap Nemaura Medical Crashed 39.5% Today

    The clinical-stage upstart is raising money via a stock offering that dilutes existing investors.

  • GlobeNewswire4 months ago

    Nemaura Publishes Positive Data from SugarBEAT® FDA Clinical Trial

    Nemaura Medical Inc. (NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by people with diabetes and pre-diabetics, today published clinical data from its recently completed study intended to support a De Novo submission to the U.S Food & Drug Administration (“FDA”) for approval of its sugarBEAT® product. The global addressable market for CGM is estimated at $82B per annum, with the U.S. the largest single market estimated at $13B.

  • GlobeNewswire4 months ago

    Nemaura Medical Announces Pricing of Up to $2.5 Million Public Offering

    Nemaura Medical Inc. (NMRD), a medical technology company developing sugarBEAT® as a non-invasive affordable and flexible Continuous Glucose Monitor (CGM) for use by people with diabetes and pre-diabetics, today announced the pricing of a "best efforts" public offering of  Company's shares of common stock and warrants with expected total gross proceeds of up to $2.5 million. The offering is expected to close on or about December 20, 2018, subject to satisfaction of customary closing conditions. The offering was priced at $1.04 per share of common stock, with each share coupled with one five-year warrant to purchase one share of common stock, at an exercise price of $1.04 per share.

  • GlobeNewswire4 months ago

    Nemaura Medical Announces Proposed Public Offering

    Nemaura Medical Inc. (NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by persons with diabetes and pre-diabetics, today announced a proposed registered public offering of its common stock and warrants. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Dawson James Securities, Inc. is acting as the sole placement agent in connection with the offering.

  • GlobeNewswire4 months ago

    Nemaura to Present SugarBEAT® Clinical Performance Poster at ATTD, Berlin

    Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by people with diabetes and pre-diabetics, today announced that the Advanced Technologies and Treatments for Diabetes (ATTD) Conference has accepted its sugarBEAT® Clinical Performance Data Abstract for poster presentation at Berlin in February 2019. ATTD is the leading international forum for clinicians to present and discuss the use of new technologies with the goal of improving the care of people with diabetes at the fastest possible pace, and has become synonymous with top calibre scientific programs. Nemaura has also recently completed the clinical studies required for sugarBEAT® FDA De Novo 510(k) submission, and anticipates publishing this data on its website in the coming weeks, and submitting for FDA approval in March 2019.

  • GlobeNewswire5 months ago

    Nemaura Successfully Completes Clinical Studies for SugarBEAT® FDA De-Novo 510(k) Submission

    Nemaura Medical Inc. (NMRD), a medical technology company developing sugarBEAT® as a non-invasive affordable and flexible Continuous Glucose Monitor (CGM) for use by people with diabetes and pre-diabetics, today reported that it has successfully completed the clinical studies needed to support a De-Novo 510(k) submission to the U.S. Food & Drug Administration (“FDA”) for approval of its sugarBEAT® product. The global addressable market for CGM is estimated at $82B per annum, with the U.S. market estimated at $13.5B.

  • GlobeNewswire5 months ago

    Nemaura Signs License and Distribution Agreement for SugarBEAT® Commercial Launch in Qatar

    LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose.

  • GlobeNewswire5 months ago

    Nemaura Medical to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum

    Nemaura Medical Inc. (NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible continuous glucose monitor (CGM) for use by people with diabetes and pre-diabetics, today announced that Chief Business Officer, Bashir Timol, will be presenting at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 15, 2018 in New York.

  • GlobeNewswire5 months ago

    Nemaura Medical to Present at the Stifel 2018 Healthcare Conference

    Nemaura Medical Inc. (NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible continuous glucose monitor (CGM) for use by people with diabetes and pre-diabetics, today announced that Chief Business Officer, Bashir Timol, will be presenting at the Stifel 2018 Healthcare Conference on Tuesday, November 13, 2018 in New York.

  • GlobeNewswire6 months ago

    Nemaura Medical Inc. Reports Second Quarter 2018 Financial Results

    Nemaura Medical Inc. (NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible continuous glucose monitor (CGM) for use by people with diabetes and pre-diabetics recently reported financial results for the second quarter ended September 30, 2018. Dr. Faz Chowdhury, CEO of Nemaura Medical commented “we have maintained our well capitalised financial position to better support the expected commercial launch of sugarBEAT® in the United Kingdom in the coming weeks.

  • GlobeNewswire6 months ago

    Nemaura Successfully Develops Predictive Algorithms and Alarm Functionality for Continuous Glucose Monitor SugarBEAT®

    LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive affordable and flexible Continuous Glucose.